Enliven Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 19.37 million compared to USD 9.55 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 2.91 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.04 USD | -3.23% | -1.66% | +66.47% |
05-14 | Enliven Therapeutics Q1 Loss Narrows | MT |
04-11 | Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.47% | 1.08B | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.33% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023